iShares S&P GSCI Commodity-Indexed Trust ETF vs Eli Lilly And Co — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.04 (market cap $1.02B), while Eli Lilly And Co trades at $1,173.23 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 1019.6× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 41 Days and Eli Lilly And Co for 93 Days on average.
| GSG | LLY | |
|---|---|---|
Market Cap | $1.02B | $1.04T |
Volume | 1,256,221 | 3,064,878 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $1.28K |
52-Week Low | $22.45 | $799.57 |
Typical Hold Time | 41 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →